Collectively, BrMs presence showed limited impact on the efficacy of anti-PD-1/PD-L1based combination therapy but the impact of BrMs presence on efficacy of anti-PD-1/PD-L1monotherapy in NSCLC still remains undetermined. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.